DE69430930T2 - Substitutierte Pyrazolyl-Benzolsulfonamide zur Verwendung in der Behandlung von Entzündungen - Google Patents

Substitutierte Pyrazolyl-Benzolsulfonamide zur Verwendung in der Behandlung von Entzündungen

Info

Publication number
DE69430930T2
DE69430930T2 DE69430930T DE69430930T DE69430930T2 DE 69430930 T2 DE69430930 T2 DE 69430930T2 DE 69430930 T DE69430930 T DE 69430930T DE 69430930 T DE69430930 T DE 69430930T DE 69430930 T2 DE69430930 T2 DE 69430930T2
Authority
DE
Germany
Prior art keywords
inflammation
treatment
substituted pyrazolyl
pyrazolyl benzenesulfonamides
benzenesulfonamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69430930T
Other languages
English (en)
Other versions
DE69430930D1 (de
Inventor
John J Talley
Thomas D Penning
Paul W Collins
Rogier, Jr
James W Malecha
Julie M Miyashiro
Stephen R Bertenshaw
Ish K Khanna
Matthew J Granets
Kathy L Rogers
Jeffery S Carter
Stephen H Docter
Stella Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26857022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69430930(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/160,594 external-priority patent/US5466823A/en
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69430930D1 publication Critical patent/DE69430930D1/de
Publication of DE69430930T2 publication Critical patent/DE69430930T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69430930T 1993-11-30 1994-11-14 Substitutierte Pyrazolyl-Benzolsulfonamide zur Verwendung in der Behandlung von Entzündungen Expired - Lifetime DE69430930T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/160,594 US5466823A (en) 1993-11-30 1993-11-30 Substituted pyrazolyl benzenesulfonamides
US08/223,629 US5521207A (en) 1993-11-30 1994-04-06 Substituted pyrazolyl benzenesulfonamide for the treatment of inflammation

Publications (2)

Publication Number Publication Date
DE69430930D1 DE69430930D1 (de) 2002-08-08
DE69430930T2 true DE69430930T2 (de) 2003-02-20

Family

ID=26857022

Family Applications (6)

Application Number Title Priority Date Filing Date
DE69432193T Expired - Lifetime DE69432193T2 (de) 1993-11-30 1994-11-14 Substituierte Pyrazolyl-benzolsulfonamide und ihre Verwendung als CyclooxygenaseII Inhibitoren
DE2000175033 Active DE10075033I2 (de) 1993-11-30 1994-11-14 substituierte Pyrazolyl-benzolsulfonamide zur Behandlung von Entzündungen.
DE69430930T Expired - Lifetime DE69430930T2 (de) 1993-11-30 1994-11-14 Substitutierte Pyrazolyl-Benzolsulfonamide zur Verwendung in der Behandlung von Entzündungen
DE69422306T Expired - Lifetime DE69422306T4 (de) 1993-11-30 1994-11-14 Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
DE69422306A Expired - Lifetime DE69422306D1 (de) 1993-11-30 1994-11-14 Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
DE69429836T Expired - Lifetime DE69429836T2 (de) 1993-11-30 1994-11-14 Tricyclische,substituierte Pyrazolyl- benzolsulfonamide und ihre Verwendung als Cyclooxygenase II Inhibitoren

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69432193T Expired - Lifetime DE69432193T2 (de) 1993-11-30 1994-11-14 Substituierte Pyrazolyl-benzolsulfonamide und ihre Verwendung als CyclooxygenaseII Inhibitoren
DE2000175033 Active DE10075033I2 (de) 1993-11-30 1994-11-14 substituierte Pyrazolyl-benzolsulfonamide zur Behandlung von Entzündungen.

Family Applications After (3)

Application Number Title Priority Date Filing Date
DE69422306T Expired - Lifetime DE69422306T4 (de) 1993-11-30 1994-11-14 Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
DE69422306A Expired - Lifetime DE69422306D1 (de) 1993-11-30 1994-11-14 Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
DE69429836T Expired - Lifetime DE69429836T2 (de) 1993-11-30 1994-11-14 Tricyclische,substituierte Pyrazolyl- benzolsulfonamide und ihre Verwendung als Cyclooxygenase II Inhibitoren

Country Status (26)

Country Link
US (2) US5760068A (de)
EP (1) EP0731795B1 (de)
JP (3) JP3025017B2 (de)
KR (3) KR100229343B1 (de)
CN (4) CN1268614C (de)
AT (4) ATE212985T1 (de)
CA (4) CA2276945C (de)
CY (2) CY2237B1 (de)
CZ (1) CZ294630B6 (de)
DE (6) DE69432193T2 (de)
DK (3) DK0923933T3 (de)
ES (4) ES2172959T3 (de)
FI (1) FI115053B (de)
FR (1) FR09C0007I2 (de)
GR (1) GR3032696T3 (de)
HK (2) HK1013649A1 (de)
HU (1) HU223824B1 (de)
LU (2) LU90698I2 (de)
NL (1) NL300024I2 (de)
NO (1) NO306460B1 (de)
NZ (3) NZ536355A (de)
PL (1) PL180717B1 (de)
PT (3) PT924201E (de)
RO (1) RO118291B1 (de)
RU (1) RU2139281C1 (de)
WO (1) WO1995015316A1 (de)

Families Citing this family (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716991B1 (en) * 1993-11-30 2004-04-06 G. D. Searle & Co. Process for preparing a substituted pyrazolyl benzenesulfonamide for the treatment of inflammation
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
AU3815495A (en) * 1994-11-08 1996-05-31 Eisai Co. Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
US6429221B1 (en) * 1994-12-30 2002-08-06 Celgene Corporation Substituted imides
WO1996037476A1 (en) * 1995-05-25 1996-11-28 G.D. Searle & Co. Method of preparing 3-haloalkyl-1h-pyrazoles
EP0828718A1 (de) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo-substituierte hydroxaminsäurederivate als cyclooxygenase-2 und 5-lipoxygenase inhibitoren
US6342510B1 (en) * 1995-06-12 2002-01-29 G. D. Searle & Co. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitors and a leukotriene B4 receptor antagonist
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US5756529A (en) * 1995-09-29 1998-05-26 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
GB9520584D0 (en) * 1995-10-09 1995-12-13 Fujisawa Pharmaceutical Co Pyrazole derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
BR9611047A (pt) * 1995-10-17 2000-03-08 Searle & Co Processo de deteção de ciclo oxigenase-2
JP2000504723A (ja) 1996-02-13 2000-04-18 ジー．ディー．サール アンド カンパニー シクロオキシゲナーゼ―２阻害剤および５―リポキシゲナーゼ阻害剤投与の免疫抑制効果
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
AU2250097A (en) 1996-02-13 1997-09-02 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
TR199802049T2 (xx) * 1996-04-12 1999-01-18 G.D.Searle & Co. COX-2 Inhibit�rlerinin �nilac� olarak s�bstit�e edilmi� benzens�lfonamid t�revleri.
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
EP1479385B1 (de) * 1996-10-15 2008-07-02 G.D. Searle LLC Verwendung von Cyclooxygenase-2 Inhibitoren zur Behandlung und Vorbeugung von Neoplasia
IT1287174B1 (it) * 1996-11-15 1998-08-04 Angelini Ricerche Spa Diaril-ciclometilenpirazoli farmacologicamente attivi,procedimento per prepararli e composizioni farmaceutiche che li contengono
EP0941080A2 (de) * 1996-11-19 1999-09-15 G.D. SEARLE & CO. Verwendung von cyclooxygenase-2 hemmern als anti-angiogene mittel
DK0971714T3 (da) * 1997-04-03 2002-11-04 Searle & Co Metode til anvendelse af cyklooxygenase-2-inhibitorer til behandling og forebyggelse af demens
EE9900517A (et) * 1997-04-18 2000-06-15 G.D. Searle & Co. Tsüklooksügenaas-2 inhibiitorite kasutamise meetod südameveresoonkonna haiguste ärahoidmiseks
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
AU750356B2 (en) * 1997-09-24 2002-07-18 Fujisawa Pharmaceutical Co., Ltd. 1,5-diphenylpyrazole derivatives
AUPO941497A0 (en) * 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AUPP042397A0 (en) * 1997-11-18 1997-12-11 Fujisawa Pharmaceutical Co., Ltd. 5-arylpyrazole compounds
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
NZ333399A (en) 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
AU3387999A (en) * 1998-04-08 1999-10-25 Abbott Laboratories Pyrazole inhibitors of cytokine production
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
USRE39708E1 (en) 1998-08-07 2007-06-26 Chiron Corporation Estrogen receptor modulators
WO2000025779A1 (en) * 1998-11-02 2000-05-11 Merck & Co., Inc. Method of treating migraines and pharmaceutical compositions
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20010024664A1 (en) * 1999-03-19 2001-09-27 Obukowicz Mark G. Selective COX-2 inhibition from edible plant extracts
WO2000066562A1 (en) * 1999-05-03 2000-11-09 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
CO5261541A1 (es) * 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
JP2002544229A (ja) * 1999-05-17 2002-12-24 アイレックス オンコロジー， インコーポレイテッド 癌の化学的予防および治療のために組み合わせたｄｆｍｏおよびセレコキシブ
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
DE60018792T2 (de) 1999-12-03 2006-01-26 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonylpyrazolderivate zur verwendung als anti-imflammatorische oder analgetische verbindungen
EP1104758B1 (de) 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylenderivate zur Verwendung als schmerzstillendes oder entzündungshemmendes Mittel
TR200302047T4 (tr) 1999-12-03 2004-01-21 Pfizer Products Inc. Anti-iltihabik / analjezik maddeler olarak heteroaril fenil pirazol bileşikleri.
ATE234299T1 (de) 1999-12-03 2003-03-15 Pfizer Prod Inc Sulfamoylheteroarylpyrazolverbindungen zur verwendung als analgetisches/entzündungshemmendes mittel
YU57801A (sh) * 1999-12-08 2005-07-19 Pharmacia Corporation Polimorfni kristalni oblici celecoxib-a
UA74539C2 (en) * 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
BR0008058A (pt) * 1999-12-08 2002-03-26 Pharmacia Corp Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
JP2003523954A (ja) * 1999-12-08 2003-08-12 ファルマシア コーポレイション 治療効果が迅速に開始されるシクロオキシゲナーゼ−２阻害剤組成物
EP1246621A4 (de) 1999-12-23 2004-11-24 Nitromed Inc Nitrosierte und nitrosylierte cyclooxygenase-2-inhibitoren, zusammensetzungen und methoden für deren verwendung
AU2001244608A1 (en) * 2000-03-31 2001-10-15 Takeda Chemical Industries Ltd. Fused heterocyclic derivatives, their production and use
WO2001081333A2 (en) * 2000-04-25 2001-11-01 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
US6403629B2 (en) * 2000-05-02 2002-06-11 J.B. Chemical And Pharmaceuticals Limited Heterocyclic compounds for therapeutic use
MY120279A (en) * 2000-05-26 2005-09-30 Pharmacia Corp Use of a celecoxib composition for fast pain relief
CN100588395C (zh) * 2000-06-13 2010-02-10 Wyeth公司 含有环氧化酶-2抑制剂的止痛和抗炎药物
TR200001872A3 (tr) 2000-06-26 2002-01-21 Fako Ilaclari A.S 4-[5-(4-Metilfenil-3-(triflorometil)-1H-pirazol-1-il] benzensulfonamit' in yeni kristal biçimi "Biçim I" ve bu ürünün üretilmesine iliskin yöntem.
CA2414674A1 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
PT1303265E (pt) 2000-07-20 2007-10-09 Lauras As ''utilização de inibidores da cox-2 como imuno-estimulantes, no tratamento do vih ou da sida''
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US20020122836A1 (en) * 2000-12-15 2002-09-05 Pharmacia Corporation Selective COX-2 inhibition from non-edible plant extracts
AU2002229074A1 (en) * 2000-12-15 2002-06-24 Pharmacia Corporation Selective cox-2 inhibition from plant extracts
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20050143360A1 (en) * 2001-02-02 2005-06-30 Joel Krasnow Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
ITMI20010733A1 (it) 2001-04-05 2002-10-05 Recordati Chem Pharm Uso di inibitori dell'isoenzina cox-2 per il trattamento dell'incontinenza urinaria
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
DE60204823T2 (de) 2001-07-05 2005-12-29 Pfizer Products Inc., Groton Heterocyclo-alkylsulfonyl Pyrazole als entzündungshemmende/analgetische Mittel
DE10135027A1 (de) * 2001-07-18 2003-02-06 Solvay Pharm Gmbh Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0119477D0 (en) * 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor
CA2456939A1 (en) * 2001-08-10 2003-02-20 Pharmacia Corporation Carbonic anhydrase inhibitors
US20030220376A1 (en) * 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US20040067992A1 (en) * 2001-08-10 2004-04-08 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia
US20030114416A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
US20030114418A1 (en) * 2001-08-14 2003-06-19 Pharmacia Corporation Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
US20050101563A1 (en) * 2001-08-14 2005-05-12 Pharmacia Corporation Method and compositions for the treatment and prevention of pain and inflammation
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
JP2005506983A (ja) * 2001-09-19 2005-03-10 ファルマシア・コーポレーション 炎症の治療のための置換ピラゾリル化合物
GT200200188A (es) * 2001-09-24 2003-06-25 Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
DE10162121A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Pyrazolyl-Benzolsulfonamide sowie diese Verbindungen enthaltende Arzneimittel
US20040062823A1 (en) * 2001-12-13 2004-04-01 Obukowicz Mark G. Selective cox-2 inhibition from non-edible plant extracts
US20040126438A1 (en) * 2001-12-13 2004-07-01 Obukowicz Mark G. Selective cox-2 inhibition from plant extracts
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030224006A1 (en) * 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
WO2004026235A2 (en) * 2002-09-20 2004-04-01 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
TW562937B (en) * 2002-03-26 2003-11-21 Nanya Technology Corp Method for fast determining defect type of word line
WO2003086287A2 (en) * 2002-04-08 2003-10-23 The Ohio State University Research Foundation Compounds and methods for inducing apoptosis in proliferating cells
US20040034083A1 (en) * 2002-04-18 2004-02-19 Stephenson Diane T. Combination therapy for the treatment of Parkinson's disease with cyclooxygenase-2 (COX2) inhibitor(s)
JP2005532293A (ja) * 2002-04-18 2005-10-27 ファルマシア・コーポレーション シクロオキシゲナーゼ−２（ｃｏｘ２）阻害剤を用いたパーキンソン病の治療のための単剤療法
WO2003095430A1 (en) * 2002-05-09 2003-11-20 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
IL165355A0 (en) * 2002-05-24 2006-01-15 Pharmacia Corp Synthesis of diaryl pyrazoles
IL165383A0 (en) * 2002-06-21 2006-01-15 Transform Pharmaceuticals Inc Pharmaceutical compositions with improved dissolution
US7087630B2 (en) 2002-06-27 2006-08-08 Nitromed, Inc. Cyclooxygenase 2 selective inhibitors, compositions and methods of use
WO2004002420A2 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JP2006500372A (ja) * 2002-08-19 2006-01-05 グラクソ　グループ　リミテッド 選択的ｃｏｘ−２阻害物質としてのピリミジン誘導体
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
US20050203142A1 (en) * 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040087558A1 (en) * 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
WO2004047752A2 (en) * 2002-11-26 2004-06-10 Transform Pharmaceuticals, Inc. Pharmaceutical formulations of celcoxib
CA2509605C (en) 2002-12-13 2010-10-05 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
US20040235925A1 (en) * 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
EP2339328A3 (de) 2002-12-30 2011-07-13 Transform Pharmaceuticals, Inc. Pharmazeutische kokristallisierte Celecoxib-Zusammensetzungen
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004069029A2 (en) * 2003-01-29 2004-08-19 Children's Medical Center Corporation Prevention of surgical adhesions using selective cox-2 inhibitors
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
US20060142368A1 (en) * 2003-04-08 2006-06-29 Ching-Shih Chen Compounds and methods for inducing apoptosis in proliferating cells
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
AU2004237439B2 (en) 2003-05-07 2009-09-10 Osteologix A/S Treating cartilage/bone conditions with water-soluble strontium salts
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4－芳基－5h－噻吩－2－酮衍生物、其制法和用途
GB0319037D0 (en) * 2003-08-13 2003-09-17 Glaxo Group Ltd 7-Azaindole Derivatives
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20060079566A1 (en) * 2003-10-03 2006-04-13 Ching-Shih Chen PDK-1/Akt signaling inhibitors
JP4745971B2 (ja) * 2003-10-03 2011-08-10 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター
US20060014813A1 (en) * 2003-11-26 2006-01-19 Patrick Connelly Pharmaceutical compounds that regenerate in vivo
EP1690852A1 (de) 2003-12-01 2006-08-16 Reverse Proteomics Research Institute Co., Ltd Neues targetprotein für ein antikrebsmittel und diesem entsprechendes neues antikrebsmittel (spnal)
US7070816B2 (en) 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
US7067159B2 (en) 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
TW200526641A (en) * 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
US7927821B2 (en) * 2004-04-12 2011-04-19 Takeda Pharmaceutical Company Limited Methods of screening for compounds which bind G protein-coupled receptors
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
WO2006050057A2 (en) * 2004-10-28 2006-05-11 Celgene Corporation Methods and compositions using pde4 modulators for treatment and management of central nervous system injury
WO2006056770A1 (en) 2004-11-23 2006-06-01 Pliva Hrvatska D.O.O. Extended release pharmaceutical composition of celecoxib
US20090036435A1 (en) 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US20080200527A1 (en) * 2005-06-17 2008-08-21 Carex Sa Cannabinoid Receptor Modulators
ES2525217T3 (es) * 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
HUP0500730A2 (en) * 2005-07-29 2007-02-28 Richter Gedeon Vegyuszeti Gyar 1,2-diaryl-heterocyclic compounds, their preparation, pharmaceutical compositions comprising thereof and their use
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
US7838023B2 (en) 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
US20070154542A1 (en) * 2005-12-30 2007-07-05 Cogentus Pharmaceuticals, Inc. Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
JP5528806B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008044045A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
US7998995B2 (en) 2006-12-08 2011-08-16 Exelixis Patent Company Llc LXR and FXR modulators
KR20090092307A (ko) 2006-12-22 2009-08-31 레코르다티 아일랜드 리미티드 하요도 장애에 대한 α2δ 리간드 및 ＮＳＡＩＤｓ의 복합 치료
FR2911136B1 (fr) * 2007-01-05 2009-02-20 Sanofi Aventis Sa Derives de n-(4-cyano-1h-pyrazol-3-yl)methylamine substitues leur preparation et leur application en therapeutique.
CN101626787A (zh) * 2007-01-19 2010-01-13 马林克罗特公司 诊断的和治疗的环氧合酶-2结合配体
MX2009010491A (es) * 2007-04-11 2009-11-09 Kissei Pharmaceutical Derivado heterociclico de 5 miembros y su uso para propositos medicos.
US8039502B2 (en) 2007-07-24 2011-10-18 The Ohio State University Research Foundation Anti-infective agents against intracellular pathogens
US20090062364A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched celecoxib
EP2305645B1 (de) 2008-06-20 2012-05-16 NHWA Pharma.corporation Aralkylpiperidinderivate und ihre verwendungen als schmerz- oder beruhigungsmittel
CN103965200B (zh) 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
EP2177215A1 (de) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-Kristalle von Tramadol und NSARs
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
US8686017B2 (en) * 2008-10-31 2014-04-01 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US8785466B2 (en) * 2008-10-31 2014-07-22 Loyola University Chicago Methods of using proteinacious channels to identify pharmaceutical treatments and risks, and treatments resulting therefrom
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
WO2010150144A2 (en) 2009-06-25 2010-12-29 Wockhardt Research Centre Low dose pharmaceutical compositions of celecoxib
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011050944A1 (en) 2009-10-28 2011-05-05 Ratiopharm Gmbh Formulations containing celecoxib
WO2011055233A2 (en) 2009-11-03 2011-05-12 Actavis Group Ptc Ehf Improved process for preparing celecoxib polymorph
KR101955691B1 (ko) 2010-03-30 2019-03-07 베르선 코포레이션 트롬빈 억제제로서의 다중치환된 방향족 화합물
KR102132405B1 (ko) 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
US9079899B2 (en) 2010-11-01 2015-07-14 The Ohio State University Anti-staphylococcal celecoxib derivatives
CN102746231A (zh) * 2011-04-20 2012-10-24 天津药物研究院 塞来昔布制备工艺
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
PT3495367T (pt) 2012-06-13 2020-11-12 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
WO2013187965A1 (en) 2012-06-14 2013-12-19 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of stat3
CN102746232A (zh) * 2012-07-03 2012-10-24 石药集团中诺药业（石家庄）有限公司 一种塞来昔布杂质的制备方法
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
BR112015015351B8 (pt) 2012-12-28 2022-08-23 Dow Agrosciences Llc Mistura fungicida sinérgica, composição fungicida, e método para tratamento de uma planta
US9107947B2 (en) 2013-01-31 2015-08-18 The Penn State Research Foundation Anti-cancer compositions and methods
WO2014138616A2 (en) * 2013-03-08 2014-09-12 Translational Drug Development, Llc Pyrazole compounds and methods of use thereof
RU2019101889A (ru) 2013-03-15 2019-03-28 Версеон Корпорейшн Полизамещенные ароматические соединения в качестве ингибиторов сериновых протеаз
CN105209440B (zh) 2013-03-15 2019-07-23 维颂公司 作为凝血酶抑制剂的卤代吡唑
TWI715901B (zh) 2013-04-19 2021-01-11 美商英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
CN104974091B (zh) * 2014-04-10 2018-01-02 沈阳药科大学 3‑甲基‑1,5‑二芳基吡唑类化合物及其制备方法和用途
CA2960790A1 (en) 2014-09-17 2016-03-24 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
RS64122B1 (sr) 2014-11-16 2023-05-31 Array Biopharma Inc Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata
AU2015374459A1 (en) 2014-12-30 2017-06-29 Dow Agrosciences Llc Picolinamide compounds with fungicidal activity
NZ732657A (en) 2014-12-30 2019-01-25 Dow Agrosciences Llc Picolinamides with fungicidal activity and other related compounds
KR20170099928A (ko) 2014-12-30 2017-09-01 다우 아그로사이언시즈 엘엘씨 살진균 활성을 갖는 피콜린아미드
JP6684810B2 (ja) 2014-12-30 2020-04-22 ダウ アグロサイエンシィズ エルエルシー 殺真菌剤としてのピコリンアミド化合物の使用
BR112017013608B8 (pt) 2014-12-30 2022-08-23 Dow Agrosciences Llc Picolinamidas como fungicidas
AU2016209046A1 (en) 2015-01-23 2017-07-20 Aclaris Therapeutics, Inc. Heterocyclic ITK inhibitors for treating inflammation and cancer
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN113004278B (zh) 2015-02-20 2023-07-21 因赛特控股公司 作为fgfr抑制剂的双环杂环
US10532995B2 (en) 2015-02-27 2020-01-14 Verseon Corporation Substituted pyrazole compounds as serine protease inhibitors
WO2016177776A1 (en) 2015-05-04 2016-11-10 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
US9572819B2 (en) 2015-05-28 2017-02-21 Dr. Reddy's Laboratories, Ltd. Oral composition of celecoxib for treatment of pain
CN104945388A (zh) * 2015-07-09 2015-09-30 南京大学 4-(3-(3-(4-氯香豆素)-酰腙)-5-苯基-吡唑)苯磺酰胺类衍生物的制备方法及在抗癌药物中的应用
BR112018008357A2 (pt) 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
WO2017139684A1 (en) 2016-02-10 2017-08-17 Cocoon Biotech Inc. Compositions including benzenesulfonamide-containing non-steroidal anti-inflammatory drugs silk fibroin and a gelling agent and uses thereof
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
HRP20230704T1 (hr) 2016-05-18 2023-10-27 Loxo Oncology, Inc. Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
BR112018074486A2 (pt) 2016-05-27 2019-05-28 Dr Reddy´S Laboratories Ltd composição oral de celecoxib para tratamento da dor
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI774761B (zh) 2017-05-02 2022-08-21 美商科迪華農業科技有限責任公司 用於穀物中的真菌防治之協同性混合物
WO2018204438A1 (en) 2017-05-02 2018-11-08 Dow Agrosciences Llc Use of an acyclic picolinamide compound as a fungicide for fungal diseases on turfgrasses
TW201842851A (zh) 2017-05-02 2018-12-16 美商陶氏農業科學公司 用於穀類中的真菌防治之協同性混合物
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
US10981906B2 (en) 2017-11-03 2021-04-20 Aclaris Therapeutics, Inc. Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
BR102019004480B1 (pt) 2018-03-08 2023-03-28 Dow Agrosciences Llc Picolinamidas como fungicidas
WO2019213544A2 (en) 2018-05-04 2019-11-07 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CR20200591A (es) 2018-05-04 2021-03-31 Incyte Corp Sales de un inhibidor de fgfr
JP2021534244A (ja) 2018-08-10 2021-12-09 アクラリス セラピューティクス，インコーポレイテッド ピロロピリミジンｉｔｋ阻害剤
CN111039982A (zh) * 2018-10-12 2020-04-21 南京大学 一类含新型磷脂胺骨架的吡唑磺胺衍生物的设计、合成
KR20210076072A (ko) 2018-10-15 2021-06-23 코르테바 애그리사이언스 엘엘씨 옥시피콜린아미드의 합성 방법
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
KR20220004726A (ko) 2019-05-02 2022-01-11 어클라리스 쎄라퓨틱스, 인코포레이티드 Jak 억제제로서의 치환된 피롤로피리딘
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TW202128685A (zh) 2019-10-14 2021-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4069696A1 (de) 2019-12-04 2022-10-12 Incyte Corporation Tricyclische heterocyclen als fgfr-inhibitoren
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4275692A2 (de) 2021-01-08 2023-11-15 Seoul National University R & DB Foundation Auf getrockneten zellen basierendes therapeutikum zur behandlung von osteoarthritis
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN114292235B (zh) * 2021-12-29 2023-04-14 江苏天和制药有限公司 一种地拉考昔的制备和提纯方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4146721A (en) * 1969-09-12 1979-03-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrazol-4-acetic acid compounds
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (fr) * 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5387693A (en) * 1991-08-08 1995-02-07 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole intermediate compounds
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
EP0638071B1 (de) * 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides

Also Published As

Publication number Publication date
JP2003238536A (ja) 2003-08-27
EP0731795B1 (de) 1999-12-22
KR100261669B1 (en) 2000-07-15
CN1134418C (zh) 2004-01-14
CN1141630A (zh) 1997-01-29
US5760068A (en) 1998-06-02
CZ150396A3 (en) 1996-12-11
ES2180233T3 (es) 2003-02-01
CY2009003I1 (el) 2009-11-04
HUT74180A (en) 1996-11-28
CY2009003I2 (el) 2009-11-04
NO962184L (no) 1996-05-29
RO118291B1 (ro) 2003-04-30
DE69422306D1 (de) 2000-01-27
ES2172959T3 (es) 2002-10-01
CA2277954A1 (en) 1995-06-08
HK1021935A1 (en) 2000-07-21
GR3032696T3 (en) 2000-06-30
ES2193609T3 (es) 2003-11-01
JP3921451B2 (ja) 2007-05-30
ATE219937T1 (de) 2002-07-15
RU2139281C1 (ru) 1999-10-10
HU9601455D0 (en) 1996-07-29
CN1127484C (zh) 2003-11-12
ATE187965T1 (de) 2000-01-15
WO1995015316A1 (en) 1995-06-08
NO306460B1 (no) 1999-11-08
CN1268614C (zh) 2006-08-09
DE69429836T2 (de) 2002-07-18
PL180717B1 (pl) 2001-03-30
LU90698I2 (fr) 2001-02-13
PT923933E (pt) 2002-10-31
HK1013649A1 (en) 1999-09-03
ATE212985T1 (de) 2002-02-15
JP3025017B2 (ja) 2000-03-27
LU91538I2 (fr) 2009-05-06
DE69429836D1 (de) 2002-03-21
FI962249A0 (fi) 1996-05-29
FR09C0007I1 (de) 2009-04-17
US5753688A (en) 1998-05-19
PT731795E (pt) 2000-05-31
DE69422306T2 (de) 2000-05-18
CA2276945A1 (en) 1995-06-08
CY2237B1 (en) 2003-07-04
DE69432193T2 (de) 2004-01-15
EP0731795A1 (de) 1996-09-18
DE69422306T4 (de) 2000-09-07
NZ336428A (en) 2005-02-25
PT924201E (pt) 2002-06-28
DE69432193D1 (de) 2003-04-03
CN1280126A (zh) 2001-01-17
CA2276946A1 (en) 1995-06-08
DK0924201T3 (da) 2002-05-21
CN1280125A (zh) 2001-01-17
CA2276945C (en) 2006-08-01
KR100263817B1 (ko) 2000-08-16
JP2000109466A (ja) 2000-04-18
NL300024I2 (nl) 2001-04-02
DE69430930D1 (de) 2002-08-08
PL314695A1 (en) 1996-09-16
CZ294630B6 (cs) 2005-02-16
NL300024I1 (nl) 2001-01-02
FI115053B (fi) 2005-02-28
CA2177576C (en) 1999-10-26
FR09C0007I2 (de) 2010-12-31
NO962184D0 (no) 1996-05-29
JPH09506350A (ja) 1997-06-24
DE10075033I2 (de) 2001-08-02
CN1495170A (zh) 2004-05-12
AU690609B2 (en) 1998-04-30
ATE233245T1 (de) 2003-03-15
AU1171495A (en) 1995-06-19
DK0731795T3 (da) 2000-05-15
DK0923933T3 (da) 2002-10-21
ES2141916T3 (es) 2000-04-01
FI962249A (fi) 1996-05-29
JP3445762B2 (ja) 2003-09-08
KR100229343B1 (ko) 1999-11-01
NZ276885A (en) 1999-08-30
CN1061036C (zh) 2001-01-24
HU223824B1 (hu) 2005-02-28
NZ536355A (en) 2006-08-31
CA2177576A1 (en) 1995-06-08
DE10075033I1 (de) 2001-01-18

Similar Documents

Publication Publication Date Title
DE69430930T2 (de) Substitutierte Pyrazolyl-Benzolsulfonamide zur Verwendung in der Behandlung von Entzündungen
DE69528273D1 (de) 1,2-substituierte imidazolylverbindungen zur behandlung von entzündungen
DE122006000010I1 (de) Benzocyclobutyl- oder Indanyl-Alkyl-Amino-Alkyl substituierte 3- Benzazepin-2-ones, verwendbar in der Behandlung von kardiovaskularen Krankheiten
DE69328474T2 (de) Verwendung von substituierten Adeninderivaten zur Behandlung von MultipleSklerose
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
ATE214923T1 (de) Verwendung von (r)-verapamil als medizin zur behandlung von angina
ATE105186T1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
NO954115L (no) Anvendelse av ceruletid-dietylaminsalt ved behandling av psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition